# Starmab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/starmab

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.starmabbio.com
- Total disclosed funding: $15M
- Latest round: Series A (Feb 14, 2023)
- Investors on record: 4

## About

Based in Suzhou, China, and founded in 2020, Starmab operates as a developer of anti-infective macromolecules, focusing on the research and development of anti-infective macromolecules. The company is co-founded by Fosun Pharmaceuticals, Chongqing Yuyou Pharmaceuticals, Dr. Maomao An and Dr. Bohua Li. In February 2023, Starmab raised CNY 100 million in series A funding led by new investor Fosun Health Capital, with participation from other new investors Yaoyou Pharmaceutical, Shanghai LEM Advertising, Tongdu Investment, and other individual investor. In March 2025, it closed a venture funding from new investors Huahai Pharmaceutical and Guolian Group.

The company focuses on the development of anti-infective macromolecules, with 6 research and development pipelines. The pipelines involves gram-positive bacteria, gram-negative bacteria, fungi and viruses. Starmab has launched anti-MRSA bloodstream infection single domain antibody fusion protein XJ101 and Streptococcus pneumoniae neutralizing antibody XJ103, which can improve cure rates for severe MRSA and Streptococcus pneumoniae infections.

The company generates revenue by ??licensing proprietary biologic technologies, securing strategic partnerships for clinical development, and monetizing milestone payments from pipeline advancements??.

## Funding rounds

- Series A, Feb 14, 2023, $15M — Shanghai LEM Advertising, Fosun Health Capital, Tongdu Investment, Yaoyou Pharmaceutical

## Investors

- Shanghai LEM Advertising — Series A
- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Series A
- Tongdu Investment — Series A
- Yaoyou Pharmaceutical — Series A